Latest Clinical Trials on Stem Cell Therapy for Heart Failure (2024 Update)

Introduction

Stem cell therapy continues to show promise as a regenerative treatment for heart failure (HF), with over 50 active clinical trials worldwide in 2024. This article provides an up-to-date review of the most significant ongoing and recently completed trials, analyzing their approaches, preliminary results, and implications for the future of cardiac regeneration.

Key Ongoing Clinical Trials

**1. CONCERT-HF (NCT02501811)

• Phase: Phase II (Completed 2023, results pending)

• Therapy: Combination of autologous mesenchymal stem cells (MSCs) + c-kit+ cardiac progenitor cells (CPCs)

• Key Features:

  • First trial testing synergistic effects of two cell types

  • Targeted patients with ischemic cardiomyopathy (LVEF ≤40%)

  • Delivery via transendocardial injection using NOGA mapping

**2. DREAM-HF-2 (NCT04476901)

• Phase: Phase III (Estimated completion: Dec 2024)

• Therapy: Allogeneic mesenchymal precursor cells (MPCs, rexlemestrocel-L)

• Breakthrough Designation: FDA granted in 2022 based on:

  • 33% reduction in MACE (major adverse cardiac events) in DREAM-HF

  • Particularly effective in patients with high CRP levels (inflammatory phenotype)

**3. iPSC-CMs for HFrEF (NCT04945018)

• Phase: Phase I/IIa (First-in-human, Japan)

• Therapy: iPSC-derived cardiomyocyte spheroids

• Innovation:

  • 3D cell clusters (∼1 million cells/μL) for better engraftment

  • Immunosuppression protocol with tacrolimus + mycophenolate

  • Early results show no teratomas at 6-month follow-up

Recently Completed Trials (2023-2024)

Emerging Delivery Technologies in Trials

**1. CardiAMP-HF II (NCT05182008)

• Uses autologous bone marrow cells with a proprietary amplification protocol

• Novel catheter-based delivery with real-time viability sensing

**2. BioVAT-HF (NCT05210530)

• Combines MSCs with decellularized extracellular matrix (ECM) patch

• Surgically implanted during CABG

**3. NANEX (NCT05345097)

• Exosome-coated stem cells for enhanced retention

• Early data shows 3× higher cell survival at 4 weeks

Patient Selection Trends in New Trials

1. Phenotype-Specific Enrollment

   • HFpEF vs HFrEF sub-studies (MASTERS-2 showed better HFpEF response)

   • Inflammatory markers (CRP >2 mg/L) predicting better MPC response

2. Comorbidity Focus

   • Dedicated trials for:

     • Diabetic cardiomyopathy (CELL-D-HF, NCT05157400)

     • Chemotherapy-induced cardiotoxicity (CARDIOPROTECT, NCT05224505)

Safety Updates (2024 Pooled Analysis)

• Major concerns:

  • Ventricular arrhythmias (2.1% in iPSC trials vs 0.4% MSC trials)

  • Microvascular obstruction (3 cases per 1000 intracoronary injections)

• No increased mortality vs control in any recent trial

Future Directions

1. Gene-Edited Stem Cells

   • NCT05554883: CRISPR-modified MSCs with enhanced SDF-1 expression

2. Off-the-Shelf Allogeneic Products

   • NCT05809241: Frozen MSC-derived extracellular vesicles (EVs)

3. Combination with RNA Therapy

   • NCT06012045: miR-199a-loaded exosomes + CPCs

Conclusion

The 2024 clinical trial landscape demonstrates three key advances:

1. Combination therapies (cells + biomaterials) showing enhanced efficacy

2. iPSC-derived treatments moving to clinical reality

3. Precision patient selection improving outcomes

While no stem cell product has yet received full FDA approval for HF, multiple therapies are in Phase III with potential market entry by 2026.